Margaret Byrne

Dr. Margaret Byrne


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
GCGerald Clamon
Gerald Clamon
MBMargaret Byrne
Margaret Byrne
ETErin Talbert
Erin Talbert
Cachexia is a common complication of cancer and is associated with poor quality of life and a decrease in survival. Many patients with cancer cachexia suffer from inflammation associated with elevated cytokines, such as interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor (TNF). Single-agent trials to treat cancer cachexia have not led to substantial benefit as the type of cytokine which is elevated has rarely been specified and targeted. Cachexia may also be multifactorial, involving inflammation, anorexia, catabolism, depression, and pain, and targeting the multiple causes will likely be necessary to achieve improvement in weight and appetite. A PUBMED search revealed over 3000 articles on cancer cachexia in the past ten years. We attempted to review any studies related to inflammation and cancer cachexia identified by Google Scholar and PUBMED and further search for articles listed in their references. The National Comprehensive Cancer Network (NCCN) guidelines do not provide any suggestion for managing cancer cachexia except a dietary consult. A more targeted approach to developing therapies for cancer cachexia might lead to more personalized and effective therapy.

1 March 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
MBMargaret Byrne
Margaret Byrne
Muhammad Wasif SaifMuhammad Wasif Saif
Muhammad Wasif Saif
Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven by advances in first-line therapy but by incremental additional effects of subsequent treatment lines. To maximize outcomes, patients should receive all active agents. Identification of patient subgroups is increasing individualization of treatment. Novel oral agents, such as regorafenib and TAS-102, as well as promising immunotherapeutic agents have offered salvage treatment options for refractory mCRC. Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.

28 August 2021 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MBMargaret Byrne
Margaret Byrne
MLMathew Lucas
Mathew Lucas
LPLori Pai
Lori Pai
JBJanis Breeze
Janis Breeze
SPSusan K. Parsons
Susan K. Parsons

1 October 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
URU. Basu Roy
U. Basu Roy
MBMargaret Byrne
Margaret Byrne
JMJ. Mccoy
J. Mccoy
CBC. Blair
C. Blair
JSJ. Studts
J. Studts

20 May 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JAJamila Alazhri
Jamila Alazhri
TKTulay Koru-Sengul
Tulay Koru-Sengul
SCShuang Cai
Shuang Cai
STStacey L. Tannenbaum
Stacey L. Tannenbaum
MBMargaret Byrne
Margaret Byrne
EAEli Avisar
Eli Avisar
1034 Background: Despite the established guidelines for breast cancer treatment, there is still variability in surgical treatment after neoadjuvant therapy among women with large breast tumors, leading to variability in the outcome. Our objective was to identify possible predictors of the type of surgical treatment; mastectomy versus breast conserving surgery (BCS) in women with T3/T4 breast cancer who received neoadjuvant therapy. Methods: Population-based Florida Cancer Registry and U.S. Census from 1996 to 2009 were linked to select women diagnosed with T3/T4 breast cancer who then received neoadjuvant therapy followed by BCS or mastectomy. A multivariable logistic regression model was used to identify significant predictors of type of surgery by including sociodemographic characteristics (race, ethnicity, socioeconomic status, age, marital status, urban/rural residency), tumor characteristics (ER/PR status, histology, grade, SEER stage, regional nodes positivity), treatment facilities (hospital volume...

30 June 2026 in PLOS Medicine
Verified
Journal Article
Open access
MBMargaret Byrne
Margaret Byrne
Jill KolesarJill Kolesar
Jill Kolesar
Precision oncology is revolutionizing cancer care, but isn't reaching enough patients. Molecular tumor boards (MTBs) translate complex genomic data to more effectively inform personalized care, and a new meta-analysis shows they boost clinical outcomes. But how can we feasibly and equitably expand the use of MTBs?